arrow
G

Geoffrey McCowage

hospital for sick children (sickkids)
H指数:32
被引数:4,447

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Biological Medicines for Diffuse Intrinsic Pontine Gliomas (DIPG) Eradication (BIOMEDE). An International Randomized Phase II Biomarker-driven Platform Trial Comparing Three Targeted Therapies in Combination with Radiotherapy

弥漫性内生性脑桥胶质瘤(DIPG)清除的生物制剂(BIOMEDE)。一项国际性、随机化、II期、生物标志物驱动的平台试验,比较三种靶向疗法联合放射治疗的效果。

2025-11-010
OAAI
Molecular characterization of the SJMB12 clinical trial for children and young adults with newly diagnosed medulloblastoma

SJMB12临床试验的分子特征分析:针对新诊断髓母细胞瘤的儿童及青少年患者

2025-11-010
PRE
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (vol 30, pg 207, 2024)

复发/难治性小儿低度神经胶质瘤中的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验 (第30卷,207页,2024)

2025-04-160
OA
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial

在FIREFLY-1试验中,托瓦雷芬尼(tovorafenib)这种II型RAF抑制剂对复发性/难治性视神经通路胶质瘤患儿的放射学和视觉反应。

2024-12-190
PRE
TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG): RESULTS FROM PATIENTS ON A DRUG HOLIDAY (DH) IN THE PHASE 2 FIREFLY-1 TRIAL
2024-11-110
PRE
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE PHASE 2 FIREFLY-1 (PNOC026) TRIAL OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG)
2024-11-110
PRE
OUTCOMES OF SONIC HEDGEHOG (SHH) MEDULLOBLASTOMA (MB) IN CHILDREN AND ADULTS TREATED WITH RISK-ADAPTED THERAPY ON A PROSPECTIVE INTERNATIONAL PROTOCOL (SJMB12)
2024-06-180
OAAI
TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (PLGG): REVERSIBLE DECREASES IN GROWTH VELOCITY IN THE PHASE 2 FIREFLY-1 TRIAL

复发/难治性小儿低级别神经胶质瘤 (PLGG) 中的II型RAF抑制剂TOVORAFENIB: 2期FIREFLY-1试验中生长速度的可逆降低

2024-06-180
OAAI
PNOC022 REPORT: A COMBINATION THERAPY TRIAL USING AN ADAPTIVE PLATFORM DESIGN FOR PATIENTS WITH DIFFUSE MIDLINE GLIOMA AT INITIAL DIAGNOSIS, POST-RADIATION THERAPY, OR PROGRESSION
2024-06-180
OAAI
EFFECT OF REDUCED-DOSE CRANIOSPINAL IRRADIATION AND REDUCED-DOSE ADJUVANT CHEMOTHERAPY ON CHILDREN AND ADOLESCENTS WITH WNT MEDULLOBLASTOMA WITHOUT RESIDUAL OR METASTATIC DISEASE: RESULTS FROM THE SJMB12 CLINICAL TRIAL
2024-06-180
OAAI
Precision-guided treatment in high-risk pediatric cancers
2024-06-067
OAAI
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (vol 30, pg 207, 2024)

复发/难治性小儿低度神经胶质瘤中的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验 (第30卷,207页,2024)

2024-03-111
OAAI
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

复发/难治性小儿低级别神经胶质瘤的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验

2023-11-1740
OAAI
Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors The AIM BRAIN Project: An Australian and New Zealand Children's Haematology/Oncology Group Study

AIM BRAIN项目: 澳大利亚和新西兰儿童血液学/肿瘤学小组研究

2023-10-014
OAAI
CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOWGRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY

泛RAF抑制剂TOVORAFENIB在2期FIREFLY-1 (PNOC026) 研究的注册儿科低级别神经胶质瘤组中的临床活性

2023-06-122
OAAI
BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience
2023-04-145
OAAI